The April 2026 Justice Department order immediately moved FDA-approved marijuana products and those under state medical marijuana licenses from Schedule I to Schedule III of the Controlled Substances Act, effective late April, while directing the DEA to restart an expedited administrative rulemaking for broader rescheduling of all marijuana. This followed a December 2025 executive order prioritizing completion of the process. The DEA published a new notice of hearing that begins June 29, 2026, with a compressed schedule intended to build an evidentiary record and potentially support a final rule placing marijuana in Schedule III. Trader pricing on related contracts reflects uncertainty over the hearing’s duration, participation by interested parties, the timeline for any subsequent Federal Register publication, and risks of procedural challenges or litigation that could extend resolution beyond near-term deadlines. The outcome hinges on whether the agency completes the full rulemaking within the market’s specified window.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$766,030 Vol.
30. Juni
2%
31. Dezember
27%
$766,030 Vol.
30. Juni
2%
31. Dezember
27%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The April 2026 Justice Department order immediately moved FDA-approved marijuana products and those under state medical marijuana licenses from Schedule I to Schedule III of the Controlled Substances Act, effective late April, while directing the DEA to restart an expedited administrative rulemaking for broader rescheduling of all marijuana. This followed a December 2025 executive order prioritizing completion of the process. The DEA published a new notice of hearing that begins June 29, 2026, with a compressed schedule intended to build an evidentiary record and potentially support a final rule placing marijuana in Schedule III. Trader pricing on related contracts reflects uncertainty over the hearing’s duration, participation by interested parties, the timeline for any subsequent Federal Register publication, and risks of procedural challenges or litigation that could extend resolution beyond near-term deadlines. The outcome hinges on whether the agency completes the full rulemaking within the market’s specified window.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen